-
1
-
-
85081773249
-
-
[online]. Available from URL [Accessed 2012 Sep 11]
-
The Merck Manual: multiple myeloma [online]. Available from URL: http://www.merckmanuals.com/professional/hematology-and-oncology/plasma cell-disorders/multiple myeloma.html [Accessed 2012 Sep 11]
-
The Merck Manual: Multiple Myeloma
-
-
-
2
-
-
85081769820
-
-
American Cancer Society. Multiple myeloma [online]. Available from URL: [Accessed 2012 Sep 11]
-
American Cancer Society. Multiple myeloma [online]. Available from URL: http://www.cancer.org/Cancer/Multi pleMyeloma/DetailedGuide/multiple-myeloma- key-statistics [Accessed 2012 Sep 11]
-
-
-
-
4
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Mar 1
-
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 Mar 1; 111 (5): 2516-20
-
(2008)
Blood
, vol.111
, Issue.5
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
5
-
-
0032488846
-
The proteasome: Paradigm of a self-compartmentalizing protease
-
DOI 10.1016/S0092-8674(00)80929-0
-
Baumeister W, Walz J, Zü hl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998 Feb 6; 92 (3): 367-80 (Pubitemid 28093014)
-
(1998)
Cell
, vol.92
, Issue.3
, pp. 367-380
-
-
Baumeister, W.1
Walz, J.2
Zuhl, F.3
Seemuller, E.4
-
6
-
-
34447116376
-
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
-
DOI 10.1158/0008-5472.CAN-06-4086
-
Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007 Jul 1; 67 (13): 6383-91 (Pubitemid 47037522)
-
(2007)
Cancer Research
, vol.67
, Issue.13
, pp. 6383-6391
-
-
Demo, S.D.1
Kirk, C.J.2
Aujay, M.A.3
Buchholz, T.J.4
Dajee, M.5
Ho, M.N.6
Jiang, J.7
Laidig, G.J.8
Lewis, E.R.9
Parlati, F.10
Shenk, K.D.11
Smyth, M.S.12
Sun, C.M.13
Vallone, M.K.14
Woo, T.M.15
Molineaux, C.J.16
Bennett, M.K.17
-
7
-
-
65549136174
-
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells
-
Mar
-
Fuchs O, Provaznikova D, Marinov I, et al. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009 Mar; 9 (1): 62-77
-
(2009)
Cardiovasc Hematol Disord Drug Targets
, vol.9
, Issue.1
, pp. 62-77
-
-
Fuchs, O.1
Provaznikova, D.2
Marinov, I.3
-
8
-
-
79955498420
-
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events
-
May 1
-
Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011 May 1; 17 (9): 2734-43
-
(2011)
Clin Cancer Res
, vol.17
, Issue.9
, pp. 2734-2743
-
-
Arastu-Kapur, S.1
Anderl, J.L.2
Kraus, M.3
-
9
-
-
36148944490
-
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
-
DOI 10.1182/blood-2007-01-065888
-
Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood 2007 Nov 1; 110 (9): 3281-90 (Pubitemid 350106321)
-
(2007)
Blood
, vol.110
, Issue.9
, pp. 3281-3290
-
-
Kuhn, D.J.1
Chen, Q.2
Voorhees, P.M.3
Strader, J.S.4
Shenk, K.D.5
Sun, C.M.6
Demo, S.D.7
Bennett, M.K.8
Van Leeuwen, F.W.B.9
Chanan-Khan, A.A.10
Orlowski, R.Z.11
-
10
-
-
77954125336
-
Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies
-
Jul
-
Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010 Jul; 51 (7): 1178-87
-
(2010)
Leuk Lymphoma
, vol.51
, Issue.7
, pp. 1178-1187
-
-
Cavaletti, G.1
Jakubowiak, A.J.2
-
11
-
-
85081764557
-
-
US FDA [online]. Available from URL: [Accessed 2012 Sep 11]
-
US FDA. Kyprolis (carfilzomib) for injection: US prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda docs/label/2012/202714lbl.pdf [Accessed 2012 Sep 11]
-
Kyprolis (Carfilzomib) for Injection: US Prescribing Information
-
-
-
12
-
-
70350708810
-
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
-
Oct 15
-
Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009 Oct 15; 114 (16): 3439-47
-
(2009)
Blood
, vol.114
, Issue.16
, pp. 3439-3447
-
-
Parlati, F.1
Lee, S.J.2
Aujay, M.3
-
13
-
-
84865712581
-
A phase 1 singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
-
Jul 3
-
Alsina M, Trudel S, Furman RR, et al. A phase 1 singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. Epub 2012 Jul 3
-
(2012)
Clin Cancer Res. Epub
-
-
Alsina, M.1
Trudel, S.2
Furman, R.R.3
-
15
-
-
72549116835
-
Aphase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
-
Nov 15
-
O'Connor OA, Stewart AK, Vallone M, et al. Aphase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009 Nov 15; 15 (22): 7085-91
-
(2009)
Clin Cancer Res
, vol.15
, Issue.22
, pp. 7085-7091
-
-
O'Connor, O.A.1
Stewart, A.K.2
Vallone, M.3
-
16
-
-
80053148350
-
Pharmacokinetics pharmacodynamics metabolism distribution and excretion of carfilzomib in rats
-
Oct
-
Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011 Oct; 39 (10): 1873-82
-
(2011)
Drug Metab Dispos
, vol.39
, Issue.10
, pp. 1873-1882
-
-
Yang, J.1
Wang, Z.2
Fang, Y.3
-
17
-
-
84867323972
-
Carfilzomib pharmacokinetics safety and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: Final results [abstract no. 0890]
-
Jun
-
Niesvizky R, Vij R, Martin T, et al. Carfilzomib pharmacokinetics, safety, and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results [abstract no. 0890]. Haematologica 2011 Jun; 96 Suppl. 2: 370-1
-
(2011)
Haematologica
, vol.96
, Issue.SUPPL. 2
, pp. 370-371
-
-
Niesvizky, R.1
Vij, R.2
Martin, T.3
-
18
-
-
84875364354
-
Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]
-
May 20
-
Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
-
-
Jagannath, S.1
Vij, R.2
Stewart, K.3
-
19
-
-
84867295563
-
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
-
Jul 25
-
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. Epub 2012 Jul 25
-
(2012)
Blood. Epub
-
-
Siegel, D.S.1
Martin, T.2
Wang, M.3
-
20
-
-
84865552564
-
An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
-
Jul 30
-
Vij R, Siegel DS, Jagannath S, et al. An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. Epub 2012 Jul 30
-
(2012)
Br J Haematol. Epub
-
-
Vij, R.1
Siegel, D.S.2
Jagannath, S.3
-
21
-
-
84862507585
-
An open-label singlearm phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
-
Jun 14
-
Vij R, Wang M, Kaufman JL, et al. An open-label, singlearm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun 14; 119 (24): 5661-70
-
(2012)
Blood
, vol.119
, Issue.24
, pp. 5661-5670
-
-
Vij, R.1
Wang, M.2
Kaufman, J.L.3
-
22
-
-
85081762315
-
-
US FDA Oncologic Drugs Advisory Committee Meeting, June 20 [online]. Available from URL: [Accessed 2012 Sep 11]
-
US FDA. New Drug Application (NDA) 202714, carfilzomib (Kyprolis): Food and Drug Administration briefing document, Oncologic Drugs Advisory Committee Meeting, June 20, 2012 [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM308563.pdf [Accessed 2012 Sep 11]
-
(2012)
New Drug Application (NDA) 202714, Carfilzomib (Kyprolis): Food and Drug Administration Briefing Document
-
-
-
23
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
DOI 10.1038/sj.leu.2404284, PII 2404284
-
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 Sep; 20 (9): 1467-73 (Pubitemid 44264086)
-
(2006)
Leukemia
, vol.20
, Issue.9
, pp. 1467-1473
-
-
Durie, B.G.M.1
Harousseau, J.-L.2
Miguel, J.S.3
Blade, J.4
Barlogie, B.5
Anderson, K.6
Gertz, M.7
Dimopoulos, M.8
Westin, J.9
Sonneveld, P.10
Ludwig, H.11
Gahrton, G.12
Beksac, M.13
Crowley, J.14
Belch, A.15
Boccadaro, M.16
Turesson, I.17
Joshua, D.18
Vesole, D.19
Kyle, R.20
Alexanian, R.21
Tricot, G.22
Attal, M.23
Merlini, G.24
Powles, R.25
Richardson, P.26
Shimizu, K.27
Tosi, P.28
Morgan, G.29
Rajkumar, S.V.30
more..
-
24
-
-
85081773214
-
A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: Updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract no. 2930]
-
Dec 10-13; San Diego (CA)
-
Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract no. 2930]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 10-13; San Diego (CA)
-
(2011)
53rd Annual Meeting and Exposition of the American Society of Hematology
-
-
Papadopoulos, K.P.1
Lee, P.2
Singhal, S.3
-
25
-
-
85081768282
-
A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]
-
Jun 9-12; London
-
Siegel D, Kaufman JL, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]. 16th Congress of the European Hematology Association; 2011 Jun 9-12; London
-
(2011)
16th Congress of the European Hematology Association
-
-
Siegel, D.1
Kaufman, J.L.2
Wang, M.3
-
26
-
-
85081771781
-
-
US FDA 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: [Accessed 2012 Sep 11]
-
US FDA. Transcript of the Oncologic Drugs Advisory Committee discussion of the New Drug Application, 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM314709.pdf [Accessed 2012 Sep 11]
-
Transcript of the Oncologic Drugs Advisory Committee Discussion of the New Drug Application
-
-
-
27
-
-
85081761752
-
Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: Pooled data from four phase 2 studies [abstract no. 8086]
-
May 30
-
Nooka A, Badros A, Patel P, et al. Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: pooled data from four phase 2 studies [abstract no. 8086]. J Clin Oncol 2012 May 30; 30 (15 Suppl.)
-
(2012)
J Clin Oncol
, vol.30
, Issue.15 SUPPL.
-
-
Nooka, A.1
Badros, A.2
Patel, P.3
-
28
-
-
84867319090
-
Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction including patients on hemodialysis [abstract no. 0844]
-
Jun 1
-
Harvey RD, Lonial S, Patel P, et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract no. 0844]. Haematologica 2012 Jun 1; 97 Suppl. 1: 346
-
(2012)
Haematologica
, vol.97
, Issue.SUPPL. 1
, pp. 346
-
-
Harvey, R.D.1
Lonial, S.2
Patel, P.3
|